Oracle (ORCL) Introduces Enhancements to EDC Solution for Clinical Trials

Oracle Corporation (NYSE:ORCL) is one of the top tech stocks to buy now according to Goldman Sachs. On August 27, the company introduced “significant enhancements” to its Electronic Data Capture (EDC) solution for clinical trials. The enhanced solution is called Oracle Clinical One Data Collection. It is part of Oracle’s broader Clinical One platform, which is designed to unify various aspects of clinical research.

The updates focus on three primary areas: A new feature, the Oracle Clinical Connector, uses artificial intelligence to securely transfer data directly from Electronic Health Record (EHR) systems to the Clinical One Data Collection platform; the solution now allows research sites to upload both structured and unstructured data directly into the platform using a mobile device; and safety reporting has been integrated directly into the workflow.

These enhancements are part of Oracle’s strategy to address critical friction points in clinical research and create a more open, connected healthcare ecosystem. The company stated that its overarching goal is to reduce the burden on clinical sites, improve data integrity, and help pharmaceutical companies accelerate the process of bringing new therapies to market.

Oracle Corporation (NYSE:ORCL) is an enterprise software and cloud services company. It develops database management systems, middleware, and business applications, while also offering cloud infrastructure solutions to organizations worldwide.

While we acknowledge the potential of ORCL as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 10 Must-Buy Penny Stocks to Invest In and 6 Best Railroad Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.